Go here to learn more or to get a mailed copy.
Home » Bio
A Novel Human-to-Mouse-to-Human Approach for the Elucidation..
First-time PCF Award Recipient
Columbia University Medical Center
Targeting Neurogenesis in Prostate Cancer The prostate..
Baylor College of Medicine, Texas
Dr. Eliezer Van Allen is an Assistant..
Dr. Attard earned an MD degree from..
Gerhardt Attard, MD, PhD:
The Institute for Cancer Research – London, UK
Dr. Arredouani earned a BS Degree in..
Mohamed S. Arredouani, PhD:
Beth Israel Deaconess Hospital – Boston, MA
Dr. Armstrong earned a BS in Biomedical..
Andrew Armstrong, MD, ScM:
Duke University – Durham, NC
Preclinical assessment of mechanisms of resistance to..
Vivek Arora, MD, PhD:
Charles Sawyers, MD
Defining strategies to overcome enzalutamide (Xtandi) resistance
The organization of DNA into super-structures is..
Irfan Asangani, PhD:
University of Michigan
Arul Chinnaiyan, MD, PhD
Characterization and therapeutic targeting of MMSET in prostate cancer
Understanding resistance to new treatments for advanced,..
Emmanuel Antonarakis, MD:
Johns Hopkins University School of Medicine
Michael Carducci, MD and Jun Luo, PhD
Understanding mechanisms of response and resistance to abiraterone (Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer, by interrogation of tumor biopsies for androgen receptor splice variants.
Over 1 million prostate biopsies are performed..
Syed Adnan Ali, MD:
Mount Sinai School of Medicine
Ashutosh Tewari, MD
Intratumor Heterogeneity (ITH) in Prostate Cancer
Dr. Abida is a medical oncologist and..